PLAT and stroke disorder: Thrombolytics include recombinant tissue plasminogen activator (r-tPA), a second-generation thrombolytics, the only Food and Drug Administration (FDA)-approved pharmacotherapy for management of stroke (Jinatongthai et al., 2017).